Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesImmuron Ltd

Immuron Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.037 AUD 0.00 ( 8.82%)
Last update at 2026-11-12T01:12:00Z
VOLUME
29218
Market Cap
12.91M

Momentum Score

…

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.03
Low
0.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immuron Ltd develops and commercializes orally delivered polyclonal antibody products derived from bovine colostrum to prevent and treat gastrointestinal and infectious conditions, with a marketed product in select markets. Long-term growth may be supported by expansion of product registrations and distribution, clinical progress in additional indications and scaling of manufacturing and sales channels. Investors may find the company attractive for its differentiated non-systemic platform and the potential for recurring prophylactic demand.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
7.71M
Revenue Per Share
0.03
Gross Profit TTM
4.98M
Debt / Equity
0.01
ROE
-38.27%
Net Debt
-9.02M
ROCE
-42.25%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4.46M -5.22M -6.94M -4.18M -2.85M
Net income -3.84M -5.22M -6.94M -3.79M -2.85M
Selling general administrative - 4.48M 4.52M 4.22M 3.52M
Selling and marketing expenses - 3.45M 2.03M 0.93M 0.42M
Gross profit 4.98M 4.77M 3.34M 1.31M 0.52M
Reconciled depreciation - 0.05M 0.05M 0.05M 0.04M
Ebit - -5.36M -6.24M -3.85M -3.11M
Ebitda -4.74M -5.31M -6.19M -3.80M -3.08M
Depreciation and amortization - 0.05M 0.05M 0.05M 0.03M
Operating income -4.74M -5.34M -5.80M -6.00M -4.06M
Other operating expenses 12.45M 12.63M 10.70M 5.37M 3.64M
Interest expense 0.01M 0.01M 0.01M 0.01M 0.01M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.14M 0.33M 0.11M 0.02M
Net interest income - 0.13M 0.32M 0.11M 0.02M
Income tax expense -0.62M - -0.76M -0.39M -0.26M
Total revenue 7.71M 7.29M 4.90M 1.80M 0.77M
Total operating expenses 9.71M 10.11M 9.14M 4.88M 4.58M
Cost of revenue 2.74M 2.52M 1.57M 0.50M 0.24M
Total other income expense net 0.27M 0.13M -1.14M 1.82M 0.02M
Net income from continuing ops - -5.22M -6.94M -3.79M -2.85M
Net income applicable to common shares - -5.22M -6.94M -3.79M -2.85M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 12.99M 10.13M 15.55M 21.99M 24.86M
Other current assets 0.26M 0.01M 0.10M 0.16M 1.03M
Total liab 1.99M 2.06M 2.84M 2.37M 1.68M
Total stockholder equity 11.01M 8.07M 12.71M 19.62M 23.18M
Other current liab 0.44M 0.05M 0.56M 0.29M 0.03M
Common stock 95.66M - 88.50M 88.44M 88.44M
Capital stock - 88.87M - 88.44M 88.44M
Retained earnings -85.13M -82.44M -78.97M -72.06M -68.43M
Other liab - - - 0.00M 0.00M
Other assets - - - 1.22M 0.96M
Cash 9.02M 2.83M 11.66M 17.16M 22.11M
Total current liabilities 1.79M 1.97M 2.70M 2.22M 1.50M
Current deferred revenue - - - 0.70M 0.71M
Net debt -9.02M - -11.66M -16.97M -21.93M
Short term debt - - - 0.04M 0.03M
Short long term debt total - - - 0.19M 0.18M
Other stockholder equity - - - 0.11M 3.17M
Property plant equipment - - - 0.20M 0.23M
Total current assets 12.80M 10.02M 14.73M 20.41M 23.67M
Long term investments - - - 0.16M -
Net tangible assets - - - 19.62M 23.18M
Short term investments - - - 1.83M 1.83M
Net receivables 1.25M 0.79M 1.39M 0.42M 0.66M
Inventory 2.27M 1.77M 1.58M 0.84M 0.33M
Accounts payable 1.35M 1.01M 2.14M 1.19M 0.72M
Accumulated other comprehensive income 0.48M - 3.17M 3.24M 3.17M
Non currrent assets other - 0.00M 0.67M 1.22M 0.96M
Non current assets total 0.19M 0.11M 0.82M 1.58M 1.18M
Capital lease obligations - 0.07M - 0.19M 0.21M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -2.90M 0.33M -2.62M 0.01M
Change to liabilities - - - 0.69M 0.29M
Total cashflows from investing activities 3.03M -2.90M 0.33M -2.74M 0.01M
Net borrowings - -0.07M -0.02M -0.04M -0.04M
Total cash from financing activities 6.49M 0.20M 0.00M -0.04M -0.04M
Change to operating activities - - - 1.26M -0.49M
Net income -3.84M -5.22M -6.94M -3.79M -2.85M
Change in cash 6.19M -8.83M -5.50M -4.95M -2.94M
Begin period cash flow 2.83M 11.66M 17.16M 22.11M 25.05M
End period cash flow 9.02M 2.83M 11.66M 17.16M 22.11M
Total cash from operating activities -3.07M -6.14M -5.88M -2.49M -3.13M
Issuance of capital stock - 0.40M 0.02M 0.00M 0.00M
Depreciation - 0.05M 0.05M 0.05M 0.03M
Other cashflows from investing activities - 0.14M 0.33M -2.61M 0.02M
Dividends paid - 0.00M 0.00M 0.00M 0.00M
Change to inventory - 0.48M -0.19M -0.78M 0.28M
Change to account receivables - -0.56M -0.96M 0.23M -0.34M
Sale purchase of stock - 0.40M 0.02M 0.00M 0.00M
Other cashflows from financing activities -0.17M -0.01M -0.01M -0.04M -0.04M
Change to netincome - - - -0.26M -0.05M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.01M
Change in working capital - -0.52M -0.08M 1.40M -0.27M
Stock based compensation - 0.30M 0.00M 0.23M 0.09M
Other non cash items 0.77M -0.75M 1.09M 0.47M -0.21M
Free cash flow -3.07M -6.14M -5.56M -2.50M -3.14M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IMC
Immuron Ltd		 0.00
8.82%		 0.04 - - 1.67 1.17 0.53 1.15
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Immuron Ltd

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

62 Lygon Street, Carlton, VIC, Australia, 3053

61 3 8892 4854

https://www.immuron.com.au

7

Name Title Year Born
Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA Chief Exec. Officer 1968
Dr. Jerry Kanellos Ph.D. Chief Operating Officer 1961
Mr. Phillip Allen Hains BBus(Acc), CA, MBA CFO & Company Sec. 1959
Mr. David Lyon Head of Marketing NA
Dr. Dan Ruben Peres Chief Medical Officer 1976
Mr. Flavio Palumbo Chief Commercial Officer NA
Mr. Steven George Lydeamore CPA, M.B.A. Chief Executive Officer 1968
Mr. Flavio Palumbo Chief Commercial Officer 1974
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary 1959
Mr. Steven George Lydeamore CPA, M.B.A. Chief Executive Officer 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…